Professional Summary
Professional Overview
Beth Rogozinski is a seasoned executive with a proven track record of driving innovation and growth in the digital health and technology sectors. As the Chief Executive Officer of Oncoustics, she is responsible for leading the company's strategic direction, overseeing product development, and fostering partnerships to advance the company's mission of revolutionizing the diagnosis and management of oncological conditions.
Experience Summary
Current Roles
- Chief Executive Officer, Oncoustics (2020-09-01 to Present): Providing visionary leadership and strategic direction to Oncoustics, a pioneering digital health company developing AI-powered solutions for oncology. Responsible for driving product innovation, building strategic partnerships, and expanding the company's market presence.
- Independent Board Director, Modality.AI (2021-12-01 to Present): Serving on the board of Modality.AI, a leading provider of AI-powered digital biomarkers for clinical trials and patient monitoring.
- Digital Medicine Advisory Board, UnitedHealth Group (2020-06-01 to Present): Advising the UnitedHealth Group on the integration of digital technologies and innovative solutions within the healthcare ecosystem.
- Independent Board Director, A4i (2021-07-01 to Present): Providing strategic guidance and oversight to A4i, a company developing advanced artificial intelligence and machine learning solutions for the life sciences industry.
- Independent Board Director, Mentia, Inc. (2018-05-01 to Present): Serving on the board of Mentia, a digital health startup focused on developing cognitive assessment and brain health solutions.
Past Roles
- Advisor, Oncoustics (2018-01-01 to 2020-09-01): Provided strategic guidance and domain expertise to the company during its early stages of development.
- Chief Product and Content Officer, Pear Therapeutics (2014-01-01 to 2017-03-01): Spearheaded the development and launch of Pear's pioneering prescription digital therapeutics solutions, driving innovation and market expansion.
- Founder and CEO, Match Factor (2011-12-01 to 2013-12-01): Co-founded and led this innovative tech startup focused on personalized learning and career development.
- Founder and CEO, Transmedia SF (2011-12-01 to 2014-02-01): Established and operated this digital media and content production company, delivering cutting-edge cross-platform experiences.
- Founder and CEO, D2S GAMES (2009-08-01 to 2012-04-01): Co-founded and led this game development studio, creating engaging interactive entertainment products.
Academic Background
Beth Rogozinski holds a Bachelor of Arts degree in Multimedia Studies from San Francisco State University, where she specialized in interactive media and digital content production.
Areas of Expertise
- Digital health and medical technology
- Artificial intelligence and machine learning applications in healthcare
- Product development and innovation
- Strategic partnership building and business development
- Entrepreneurship and startup leadership
- Digital media and content strategy
Professional Impact
- Pioneered the development and commercialization of Pear Therapeutics' groundbreaking prescription digital therapeutics solutions, helping to advance the digital health industry.
- Served as a trusted advisor to several leading digital health and technology companies, contributing to the growth and success of innovative solutions.
- Demonstrated a proven track record of founding and leading successful technology startups, driving innovation and creating value for stakeholders.
- Actively contributes to the digital health ecosystem through her board-level roles, advising on the integration of cutting-edge technologies and strategies.
Conclusion
With her extensive experience in the digital health and technology sectors, Beth Rogozinski is a visionary leader who is driving the transformation of healthcare through the strategic application of innovative technologies. As the CEO of Oncoustics, she is at the forefront of developing AI-powered solutions that can revolutionize the diagnosis and management of oncological conditions, positively impacting patient outcomes and the overall healthcare landscape.
